- Home
- WMB vs REGN Comparison
WMB vs REGN Comparison
Compare WMB & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WMB | REGN |
|---|---|---|
| Founded | 1908 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.6B | 73.2B |
| IPO Year | 2002 | 1995 |
Fundamental Metrics
Financial Performance| Metric | WMB | REGN |
|---|---|---|
| Price | $70.98 | $614.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 25 |
| Target Price | $77.41 | ★ $830.16 |
| AVG Volume (30 Days) | ★ 5.6M | 1.1M |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.86% | 0.55% |
| EPS Growth | ★ 17.58 | 8.19 |
| EPS | 0.70 | ★ 6.75 |
| Revenue | ★ $11,950,000,000.00 | $5,872,227,000.00 |
| Revenue This Year | $6.97 | $12.45 |
| Revenue Next Year | $9.85 | $10.13 |
| P/E Ratio | $102.13 | ★ $91.11 |
| Revenue Growth | 13.78 | ★ 20.82 |
| 52 Week Low | $55.82 | $503.25 |
| 52 Week High | $80.08 | $821.11 |
Technical Indicators
Market Signals| Indicator | WMB | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.62 | 38.87 |
| Support Level | $69.67 | $610.60 |
| Resistance Level | $75.06 | $618.01 |
| Average True Range (ATR) | 1.52 | 14.99 |
| MACD | -0.20 | 3.37 |
| Stochastic Oscillator | 19.07 | 46.60 |
Price Performance
Historical ComparisonAbout WMB Williams Companies Inc. (The)
Williams operates the Transco pipeline, which connects the Gulf Coast to the Northeast United States. It has additional natural gas transmission pipelines connecting the Rockies to the Pacific Northwest and midcontinent. At the field level, it operates substantial gathering and processing assets in Appalachia and other basins. The company has also struck several power supply agreements.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.